arrow
N

Naseem Salahuddin

the indus hospital
H指数:23
被引数:1,763

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial

贝达喹啉、德拉马尼、利奈唑胺和氯法齐明用于利福平耐药和氟喹诺酮类耐药结核病(endTB-Q):一项开放标签、多中心、分层、非劣效性、随机对照、III期试验

2025-07-160
PREAI
Sputum culture reversion in longer treatments with bedaquiline, delamanid, and repurposed drugs for drug-resistant tuberculosis
2024-05-090
OAAI
Concordance of three approaches for operationalizing outcome definitions for multidrug-resistant TB
2023-01-016
OAAI
WHO Point Prevalence Survey to Describe the Use of Antimicrobials at a Tertiary Care Center in Pakistan: A Situation Analysis for Establishing an Antimicrobial Stewardship Program

世卫组织点名流行率调查,以描述巴基斯坦三级医疗中心抗菌药物的使用情况: 建立抗菌药物管理计划的情况分析

2022-11-046
OA
Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline, Delamanid, and Other Second-Line Drugs
2022-03-0425
OAAI